We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
Read MoreHide Full Article
Key Takeaways
Veeva Systems shows growth backed by strong Q4 FY2026 and expanding pharma deals.
VEEV saw Q4 revenue rise 16% to $836M, driven by broad Commercial and R&D adoption.
Veeva Systems faces rising operating and sales costs, expected to increase in FY2027.
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2026 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern.
This Zacks Rank #2 (Buy) company’s shares have lost 21.8% in the last year-to-date period compared with the 25.7% decline of the industry. The S&P 500 Composite has decreased 4.1% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $33.43 billion. The company anticipates 23.8% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 8.2%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Strategic Deals: During the fiscal fourth quarter, Veeva Systems continued to deepen its enterprise-level engagements, with growing traction among top global pharma customers reinforcing the platform strategy. Management highlighted steady progress toward capturing roughly 14 of the top 20 pharma companies on Vault CRM, with most decisions already made and implementations underway on a proven, live product.
Beyond CRM, the company is seeing expanding adoption across multiple applications during large migrations, with customers increasingly adding solutions like Network, OpenData, Service Center and Campaign Manager alongside core deployments. This reflects a clear shift from point solutions toward broader, multi-product platform standardization, particularly as trust in Veeva Systems’ execution and delivery model continues to strengthen.
Robust Product Portfolio: Veeva Systems closed fiscal 2026 on a strong note, with fourth-quarter revenue rising 16% year over year to about $836 million, driven by broad-based growth across both Commercial and R&D segments. The company’s momentum reflects increasing diversification, with multiple products scaling in parallel as customers adopt Veeva as a multi-product platform, deepening penetration and strengthening recurring revenue.
Vault CRM remains a key anchor with 140 customers and growing adoption among top pharma firms, supported by add-ons like Service Center and Campaign Manager, while Crossix continues to perform well despite tougher comps ahead. On the R&D side, next-gen offerings such as RTSM, EDC, Safety and LIMS are gaining traction, with key wins like top-20 pharma standardizations underscoring Veeva Systems’ expanding role in mission-critical workflows and reinforcing long-term growth visibility.
Strong Q4 Results: Veeva Systems exited the fourth quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.
Veeva Systems closed fiscal 2026 with strong momentum, delivering fourth-quarter results ahead of expectations marked by deepening partnerships and expansion with both new and existing customers. The company ended the year with a total of 1,552 customers, including 1,196 in Veeva R&D and Quality Solutions and 767 in Veeva Commercial Solutions.
Strong customer success and product innovation helped VEEV achieve a $3 billion revenue run rate in early 2025. Looking forward, solid business momentum and continued operational discipline reinforce management’s confidence in achieving the company’s $6 billion revenue run-rate objective by 2030.
A Factor That May Offset the Gains of VEEV
Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. Sales and marketing expenses for the fourth quarter of fiscal 2026 increased 11.1% year over year. Management expects sales and marketing expenses to increase in fiscal 2027, primarily due to employee-related expenses as the company raises its headcount to support its sales and marketing efforts associated with its product offerings and continued expansion of its sales capacity across all its solutions.
In the fiscal fourth quarter, the total operating expenses increased 7.1% year over year. Veeva Systems expects operating expenses to increase in fiscal 2027, primarily due to employee compensation-related costs.
Estimate Trend
Veeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $8.77.
The Zacks Consensus Estimate for first-quarter fiscal 2027 revenues is pegged at $857.3 million, indicating a 12.9% improvement from the year-ago quarter’s reported number. The EPS estimate for the first quarter of fiscal 2027 is pinned at $2.12, implying a 7.6% improvement year over year.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Reasons to Add Veeva Systems Stock to Your Portfolio for Now
Key Takeaways
Veeva Systems Inc. (VEEV - Free Report) is well-poised for growth in the coming quarters, courtesy of its strong product portfolio. The optimism, led by a solid fourth-quarter fiscal 2026 performance and strategic deals, is expected to contribute further. However, rising operational costs remain a cause for concern.
This Zacks Rank #2 (Buy) company’s shares have lost 21.8% in the last year-to-date period compared with the 25.7% decline of the industry. The S&P 500 Composite has decreased 4.1% during the said time frame.
The renowned provider of cloud-based software applications and data solutions for the life sciences industry has a market capitalization of $33.43 billion. The company anticipates 23.8% growth for the next five years and expects to maintain its strong performance in the future. It delivered a trailing four-quarter average earnings surprise of 8.2%.
Image Source: Zacks Investment Research
Reasons Favoring VEEV’s Growth
Strategic Deals: During the fiscal fourth quarter, Veeva Systems continued to deepen its enterprise-level engagements, with growing traction among top global pharma customers reinforcing the platform strategy. Management highlighted steady progress toward capturing roughly 14 of the top 20 pharma companies on Vault CRM, with most decisions already made and implementations underway on a proven, live product.
Beyond CRM, the company is seeing expanding adoption across multiple applications during large migrations, with customers increasingly adding solutions like Network, OpenData, Service Center and Campaign Manager alongside core deployments. This reflects a clear shift from point solutions toward broader, multi-product platform standardization, particularly as trust in Veeva Systems’ execution and delivery model continues to strengthen.
Robust Product Portfolio: Veeva Systems closed fiscal 2026 on a strong note, with fourth-quarter revenue rising 16% year over year to about $836 million, driven by broad-based growth across both Commercial and R&D segments. The company’s momentum reflects increasing diversification, with multiple products scaling in parallel as customers adopt Veeva as a multi-product platform, deepening penetration and strengthening recurring revenue.
Vault CRM remains a key anchor with 140 customers and growing adoption among top pharma firms, supported by add-ons like Service Center and Campaign Manager, while Crossix continues to perform well despite tougher comps ahead. On the R&D side, next-gen offerings such as RTSM, EDC, Safety and LIMS are gaining traction, with key wins like top-20 pharma standardizations underscoring Veeva Systems’ expanding role in mission-critical workflows and reinforcing long-term growth visibility.
Strong Q4 Results: Veeva Systems exited the fourth quarter of fiscal 2026 with better-than-expected results, wherein both earnings and revenues beat the Zacks Consensus Estimate. The uptick in both top and bottom lines and robust performance by the Subscription services segment during the quarter were impressive. The uptick in Professional services and others’ revenues also bodes well.
Veeva Systems closed fiscal 2026 with strong momentum, delivering fourth-quarter results ahead of expectations marked by deepening partnerships and expansion with both new and existing customers. The company ended the year with a total of 1,552 customers, including 1,196 in Veeva R&D and Quality Solutions and 767 in Veeva Commercial Solutions.
Strong customer success and product innovation helped VEEV achieve a $3 billion revenue run rate in early 2025. Looking forward, solid business momentum and continued operational discipline reinforce management’s confidence in achieving the company’s $6 billion revenue run-rate objective by 2030.
A Factor That May Offset the Gains of VEEV
Rising Costs: Veeva Systems has been experiencing rising operating costs over the past few months. Sales and marketing expenses for the fourth quarter of fiscal 2026 increased 11.1% year over year. Management expects sales and marketing expenses to increase in fiscal 2027, primarily due to employee-related expenses as the company raises its headcount to support its sales and marketing efforts associated with its product offerings and continued expansion of its sales capacity across all its solutions.
In the fiscal fourth quarter, the total operating expenses increased 7.1% year over year. Veeva Systems expects operating expenses to increase in fiscal 2027, primarily due to employee compensation-related costs.
Estimate Trend
Veeva Systems is witnessing a stable estimate revision trend for fiscal 2027. In the past 30 days, the Zacks Consensus Estimate for fiscal 2027 earnings per share (EPS) has remained stable at $8.77.
The Zacks Consensus Estimate for first-quarter fiscal 2027 revenues is pegged at $857.3 million, indicating a 12.9% improvement from the year-ago quarter’s reported number. The EPS estimate for the first quarter of fiscal 2027 is pinned at $2.12, implying a 7.6% improvement year over year.
Other Key Picks
Some other top-ranked stocks in the broader medical space are Envista (NVST - Free Report) , Globus Medical (GMED - Free Report) and BrightSpring Health Services (BTSG - Free Report) . Each stock presently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Estimates for Envista’s 2026 EPS have increased 11.9% in the past 60 days. Shares of the company have surged 44.9% in the past year against the industry’s 23.4% decline. NVST’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 16.4%. In the last reported quarter, it delivered an earnings surprise of 18.8%.
Globus Medical shares have risen 14% in the past year. Estimates for the company’s 2026 EPS have increased 11.2% to $4.46 in the past 30 days. GMED’s earnings beat estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 18.8%. In the last reported quarter, it posted an earnings surprise of 20.8%.
BrightSpring Health Services shares have soared 134.5% in the past year. Estimates for the company’s 2026 EPS have jumped 20.1% to $1.61 in the past 30 days. BTSG’s earnings topped estimates in three of the trailing four quarters and missed on one occasion, delivering an average surprise of 40.4%. It has an estimated long-term earnings growth rate of 47.2% compared with the industry’s 14.5% growth.